Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $135 | $150 | $212 | $297 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $56 | $51 | $36 | $39 |
| Inventory | $4 | $3 | $3 | $3 |
| Other Curr. Assets | $13 | $15 | $13 | $21 |
| Total Curr. Assets | $208 | $219 | $265 | $360 |
| Property Plant & Equip (Net) | $4 | $2 | $2 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $3 | $3 | $3 | $3 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $26 | $26 | $25 | $13 |
| Total NC Assets | $33 | $31 | $29 | $18 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $240 | $250 | $294 | $378 |
| Liabilities | – | – | – | – |
| Payables | $1 | $4 | $12 | $11 |
| Short-Term Debt | $1 | $22 | $18 | $20 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $91 | $66 | $45 | $55 |
| Total Curr. Liab. | $93 | $92 | $74 | $86 |
| LT Debt | $2 | $553 | $547 | $535 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $568 | $12 | $12 | $12 |
| Total NC Liab. | $570 | $564 | $559 | $546 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $1 | $0 | $0 |
| Total Liabilities | $663 | $656 | $633 | $632 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,463 | -$1,433 | -$1,357 | -$1,263 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,041 | $1,027 | $1,019 | $1,009 |
| Total Equity | -$423 | -$406 | -$338 | -$254 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $240 | $250 | $294 | $378 |
| Net Debt | -$132 | $425 | $352 | $258 |